Predictive score for the development or progression of graves' orbitopathy in patients with newly diagnosed graves' hyperthyroidism.

Conclusions: In patients without GO at diagnosis, 15% will develop GO (13% mild, 2% moderate-to-severe) during subsequent treatment with ATD for 18 months. A predictive score called PREDIGO composed of four baseline determinants, was better in predicting those patients who will not develop obvious GO than who will.
PMID: 29650691 [PubMed - as supplied by publisher]

Source: European Journal of Endocrinology - April 12, 2018 Category: Endocrinology Authors: Wiersinga WM, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O, Morris D, Fichter N, Lareida J, von Arx G, Daumerie C, Burlacu MC, Kahaly GJ, Pitz S, Beleslin B, Ćirić J, Ayvaz G, Konuk O, Balos Toruner F, Salvi M, Covelli D, Currò N, Hegedüs Tags: Eur J Endocrinol Source Type: research